Newly approved cancer drugs in China — innovation and clinical benefit
Nature Reviews Clinical Oncology, Published online: 16 January 2023; doi:10.1038/s41571-023-00728-3Around 100 new cancer drugs, defined as new molecular entities, were approved in China between 2005 and 2021. More than half of these new cancer drugs do not constitute innovations in mechanism of action or therapy and do not have documented meaningful clinical benefit. Approaches are needed to promote meaningful innovation for patients with cancer. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 16, 2023 Category: Cancer & Oncology Authors: Yichen Zhang Anita K. Wagner Xiaodong Guan Source Type: research
Epcoritamab is active in large B cell lymphomas
Nature Reviews Clinical Oncology, Published online: 16 January 2023; doi:10.1038/s41571-023-00730-9Epcoritamab is active in large B cell lymphomas (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 16, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, Published online: 13 January 2023; doi:10.1038/s41571-022-00718-xImmune-checkpoint inhibitors (ICI) constitute a paradigm shift in the treatment of non-small-cell lung cancer (NSCLC); however, identifying the minority of patients who derive long-term benefit remains problematic, particularly among those with targetable oncogenic drivers who have typically been under-represented in or excluded from clinical trials of ICIs. This Review summarizes the associations of common oncogenic drivers of NSCLC with sensitivity or resistance to ICIs as well as the underlying effects on the immune tumour...
Source: Nature Reviews Clinical Oncology - January 13, 2023 Category: Cancer & Oncology Authors: Itziar Otano Alvaro C. Ucero Jon Zugazagoitia Luis Paz-Ares Source Type: research
Humanized mouse models for immuno-oncology research
Nature Reviews Clinical Oncology, Published online: 12 January 2023; doi:10.1038/s41571-022-00721-2Preclinical models that faithfully recapitulate interactions between the human immune system and tumours are necessary to evaluate human-specific immunotherapies in vivo; however, their number is currently limited. The authors of this Review discuss the currently available humanized mouse models, which are immunodeficient mice co-engrafted with human tumours and immune components, with a focus on their applicability in translational research. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 12, 2023 Category: Cancer & Oncology Authors: Jane Chuprin Hannah Buettner Mina O. Seedhom Dale L. Greiner James G. Keck Fumihiko Ishikawa Leonard D. Shultz Michael A. Brehm Source Type: research
Therapy with oncolytic viruses: progress and challenges
Discussions of a range of novel OVs with the potential for clinical implementation in the near future are also provided. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 11, 2023 Category: Cancer & Oncology Authors: Sophia Z. Shalhout David M. Miller Kevin S. Emerick Howard L. Kaufman Source Type: research
The emerging roles of γδ T cells in cancer immunotherapy
Nature Reviews Clinical Oncology, Published online: 09 January 2023; doi:10.1038/s41571-022-00722-1γδ T cells are lymphocytes with properties of both typical αβ T cell and natural killer cells, notable tissue tropisms, and MHC-independent antitumour functions that make them attractive agents for cancer immunotherapy. In this Review, the authors provide an overview of human γδ T cell subsets, discuss the antitumour and pro-tumour activities of these cells and their prognostic value in patients with cancer, and describe the current landscape of γδ T cell-based immunotherapies. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 9, 2023 Category: Cancer & Oncology Authors: Sofia Mensurado Rafael Blanco-Dom ínguez Bruno Silva-Santos Source Type: research
From little subclones grow mighty oaks
Nature Reviews Clinical Oncology, Published online: 09 January 2023; doi:10.1038/s41571-022-00727-wNew genetic analyses demonstrate that the presence of low-frequency subclonal populations, including high-risk subclones, at diagnosis in multiple myeloma can contribute to disease relapse and poor clinical outcomes. Thus, sensitive detection approaches are required to detect these subclones at diagnosis together with innovative treatment strategies to eradicate low-frequency, high-risk subclones and prevent them from becoming dominant. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 9, 2023 Category: Cancer & Oncology Authors: Eileen M. Boyle Faith E. Davies Source Type: research
Thermal immuno-nanomedicine in cancer
Nature Reviews Clinical Oncology, Published online: 05 January 2023; doi:10.1038/s41571-022-00717-yImmunotherapies have dramatically improved the outcomes of a subset of patients with advanced-stage cancers. Nonetheless, most patients will not respond to these agents and adverse events can be severe. In this Review, the authors describe the potential to address these challenges by combining immunotherapies with currently available thermal therapies as well as by using thermal immuno-nanomedicines. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 5, 2023 Category: Cancer & Oncology Authors: Zhe Yang Di Gao Jing Zhao Gaojie Yang Ming Guo Ying Wang Xuechun Ren Jong Seung Kim Lin Jin Zhongmin Tian Xingcai Zhang Source Type: research
Advances in the clinical management of uveal melanoma
Nature Reviews Clinical Oncology, Published online: 04 January 2023; doi:10.1038/s41571-022-00714-1Although almost all patients with uveal melanoma have localized disease at diagnosis, and despite effective treatment of the primary tumour, metastatic recurrence is common and holds a dismal prognosis. Unlike its cutaneous counterpart, therapeutic advances for uveal melanoma have not been forthcoming, although the recent approval of the first systemic therapy for this disease has ushered in a new era of hope. This Review summarizes the biology of uveal melanoma and the management of primary disease, including molecular risk ...
Source: Nature Reviews Clinical Oncology - January 4, 2023 Category: Cancer & Oncology Authors: Richard D. Carvajal Joseph J. Sacco Martine J. Jager David J. Eschelman Roger Olofsson Bagge J. William Harbour Nicholas D. Chieng Sapna P. Patel Anthony M. Joshua Sophie Piperno-Neumann Source Type: research
Targeted biopsy reduces detection of clinically insignificant cancer
Nature Reviews Clinical Oncology, Published online: 04 January 2023; doi:10.1038/s41571-022-00726-xTargeted biopsy reduces detection of clinically insignificant cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 4, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Engaging results with glofitamab in DLBCL
Nature Reviews Clinical Oncology, Published online: 04 January 2023; doi:10.1038/s41571-022-00725-yEngaging results with glofitamab in DLBCL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - January 4, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Efficacy of TILs confirmed
Nature Reviews Clinical Oncology, Published online: 23 December 2022; doi:10.1038/s41571-022-00723-0Efficacy of TILs confirmed (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 23, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL
Nature Reviews Clinical Oncology, Published online: 21 December 2022; doi:10.1038/s41571-022-00724-zZanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 21, 2022 Category: Cancer & Oncology Authors: David Killock Source Type: research
Predicting tumour radiosensitivity to deliver precision radiotherapy
Nature Reviews Clinical Oncology, Published online: 07 December 2022; doi:10.1038/s41571-022-00709-yAlthough radiotherapy affects multiple cellular pathways, treatments are generally planned with the assumption that all tumours respond similarly to radiation. The authors of this Review summarize the effect of various pathways activated by radiotherapy on tumour responses to radiotherapy and present the current knowledge on genomic classifiers designed to inform treatment decisions. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 7, 2022 Category: Cancer & Oncology Authors: James M. Price Asmithaa Prabhakaran Catharine M. L. West Source Type: research
New data confirm clinical utility of ctDNA
Nature Reviews Clinical Oncology, Published online: 06 December 2022; doi:10.1038/s41571-022-00716-zNew data confirm clinical utility of ctDNA (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - December 6, 2022 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
